Downstream receptor tyrosine kinase signaling effectors (RTK effectors)

Downstream receptor tyrosine kinase (RTK) signaling effectors are a diverse group of intracellular proteins that relay biochemical signals from activated surface receptors to the nucleus and other organelles [1]. These effectors are organized into several key pathways, including the Ras/Raf/MEK/ERK (MAPK) cascade and the PI3K/AKT/mTOR pathway, which are essential for regulating cell growth, proliferation, and survival [2]. In a healthy physiological context, these pathways are tightly regulated to ensure proper cellular responses to growth factors and environmental cues [3]. However, mutations in these effector proteins, such as KRAS or BRAF, often lead to constitutive activation, which is a primary driver in many types of cancer [4]. Because of their central role in disease progression, these effectors have become major targets for drug development, resulting in the approval of numerous kinase inhibitors [5]. Despite their efficacy, targeting these downstream nodes often triggers compensatory feedback mechanisms, leading to drug resistance and necessitating combination therapy approaches [6]. Furthermore, because these pathways are vital for normal cell function, therapeutic intervention can result in significant systemic side effects [7]. (Sources: [1] Lemmon MA, Schlessinger J. Cell. 2010; [2] Manning BD, Toker A. Cell. 2017; [3] Sever R, Brugge JS. Cold Spring Harb Perspect Biol. 2015; [4] Yuan TL, Cantley LC. Oncogene. 2008; [5] Janku F, et al. Nat Rev Clin Oncol. 2018; [6] Logue JS, Morrison DK. Genes Dev. 2012; [7] Sullivan RJ, Flaherty KT. Nat Rev Clin Oncol. 2013)

Other names

RTK downstream signaling pathwaysIntracellular RTK mediatorsRTK signaling cascade componentsMAPK and PI3K/AKT pathway effectors

Inhibition of downstream kinase activity or GTPase function to block intracellular signal propagation initiated by upstream receptor tyrosine kinases.